In recent years, Advanced Therapy Medicinal Products (ATMP) have evolved into a promising and highly hoped-for medical approach to cure a broad spectrum of inherited and acquired human diseases, ranging from cancer to immunological disorders and rare diseases. However, the path from development to clinical application is not yet routine.
The conference will highlight the challenging field of gene and cell therapeutics.
Advances in development and manufacturing will be presented at ATMP 2022, as well as quality control methods and regulatory aspects: The focus is on the path to safe and beneficial advanced therapies for the patient.
You are cordially invited to contribute to the scientific programme.
Abstract submissions are possible until December 15th, 2021.
Please prepare 1-2 pages (incl. figures, max. size 1 MB, max. 2 pages).
The abstract should explicitly mention objectives, new results and conclusions or
significance of the work.
Accepted abstracts will be published for all conference participants in a book of abstracts (PDF). The congress language is English.
Please use the Template to correctly format your contribution and upload it as PDF file.
Enter the author list (author and co-author/s) and affiliations in the same order as in your abstract.
Please note: DECHEMA will not make any adjustments regarding the author information.
The information will be used for the conference documents as given.
The selection of the presentations (lectures and posters) will be based on the review of the abstracts by the Scientific Committee.
Please note: Registration fee cannot be waived for authors.
1) No VAT requested according to § 4.22 UStG, registration fee may include Business Package with VAT.
2) Personal DECHEMA-, VDI-GVC-members and EFC/EFCE passport holders; personal VAAM members
Online registration is expected to be available in March 2022.
The DECHEMA terms and conditions for conferences apply. Please note that the following informations are excerpts and supplements to the general terms and conditions.
Registration is possible, subject to capacity in the lecture rooms, up to the beginning of the conference. Confirmation of registration will be sent immediately by mail. The invoice, with payment confirmation, you will receive by post mail within two weeks.
Editorial deadline for the list of participants is 30 April 2022.
The registration fees include conference ticket, book of abstracts and list of participants.
All documents will be handed out on-site.
Cancellations are only accepted in writing (i.e. by fax, surface mail or e-mail).
Please find details about cancellation dates and fees in the general terms and conditions. In case of no-show the conference fees won't be refunded and fees not yet paid still have to be paid.
For companies / institutions interested in exhibiting at the ATMP 2022 conference, we offer the following standard package:
Exhibition package: 1.500,00 € (excluding VAT)
The conference will highlight the challenging field of gene and cell therapeutic approaches, especially focusing on the following topics:
(iBET & ITQB-NOVA, Oeiras/PT)
(University Hospital of Würzburg/D)
(CEVEC Pharmaceuticals GmbH, Köln/D)
(Curexsys GmbH, Göttingen/D)
(MHH Medizinische Hochschule Hannover/D)
(BioNTech SE, Mainz/D)
(Proteona GmbH, Cologne/D and Proteona Pte. Ltd. Singapore)
Kilian Schober, (Universitätsklinikum Erlangen/D)
Keynote lecture: "Engineering T cell receptors for adoptive cell therapy”
His statement: „Engineering T cells through precise replacement of T cell receptors has now become technically possible. The challenge for the future is to make this process broadly applicable to many patients in a fast and Good Manufacturing Practice-compatible manner.”
Miltenyi Biotec GmbH, Bergisch Gladbach
Helmholtz Centre for Infection Research, Braunschweig
Anna Katharina Heide
Fraunhofer IPA, Stuttgart
University of Natural Resources and Life Sciences, Vienna
BioMedTech, Forschungscampus Reutlingen
University of Bielefeld
Technical University Hamburg
University of Applied Sciences Mittelhessen, Gießen
Miltenyi Biotec GmbH, Teterow
DECHEMA e.V., Frankfurt am Main
OPTIMA pharma GmbH, Schwäbisch Hall
Technical University Braunschweig
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
The challenges and issues of manufacturing and analytics of gene and cell therapeutics are very different from all other therapeutics, including biopharmaceuticals. A key factor of success is the management of multiple challenges addressing safety, purity and potency of these advanced therapies.
Robust and reliable manufacturing processes are still far from routine. Efficient gene transfer vectors, delivering the therapeutic gene into the target cells without causing any associated pathogenic effect, need to be developed and produced in large-scale.
Depending on the complexity and individuality of this product class, cell therapy manufacturing processes may comprise consistent procedures of culture, expansion, genetic manipulation, stimulation, and in case of treatments of multiple patients, cell banking. Analytics and quality control need to be adapted to this broad range of complex manufacturing processes ensuring adequate safety, purity and potency of the final products.
The conference is an initiative of the DECHEMA working groups Cell Culture Technology and Medical Biotechnology.